With 99% of actionable sleep therapy registrations remediated globally, the company updates its remediation process and status for ventilators.
Key takeaways:
- The Philips Respironics’ US patient portal for recall-affected CPAP and BiPAP devices is no longer available as of Jan 1, 2026.
- As of Feb 2, 2026, Philips reports 2.683 million sleep therapy patients in the US have been remediated.
- Ventilator remediation remains ongoing, with coordination handled directly through durable medical equipment providers.
- Testing concluded that use of the sleep therapy devices is not expected to result in appreciable harm to health.
As a result of progress in the June 2021 recall remediation, Philips Respironics has announced that the US patient portal for affected CPAP and BiPAP devices is no longer available as of Jan 1, 2026.
The company reports that it has remediated 99% of actionable sleep therapy device registrations globally. In the US, data as of Feb 2, 2026, indicates that 2.683 million patients have been remediated out of 2.691 million actionable registrations.
Philips defines remediated patients as those who have received a new, recertified, or alternative device; those who had devices shipped to their durable medical equipment (DME) provider handling the remediation; or those who received financial payment.
Despite the portal closure, Philips states it will continue to prioritize the remediation of registered sleep and respiratory care devices. The company plans to make multiple attempts to secure necessary information from patients with actionable registrations to complete orders and provide remediation options. Returned affected devices will also continue to be accepted at no cost.
Ventilator Remediation Updates
Remediation efforts for ventilator devices are ongoing. As of Feb 2, 2026, there are 133,000 US actionable registrations for ventilators, with 79,000 devices remediated through financial compensation or device rework options.
Philips Respironics notes that it will communicate directly with DMEs regarding ventilator updates. Patients and caregivers with affected ventilation devices do not need to take action, as all ventilation remediation will be conducted via DMEs.
Safety Testing and Cleaning Protocols
Based on results to date, Philips Respironics and third-party experts have concluded that the use of the affected sleep therapy devices is not expected to result in appreciable harm to patient health. Further testing related to both sleep therapy and ventilator devices remains ongoing.
The company also reiterates that ozone and UV light cleaning products are not approved cleaning methods for its sleep apnea devices, ventilators, or masks and should not be used.
